Estrella Immunopharma, Inc.
NASDAQ: ESLAW0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Cheng Liu
- Employees
- 3
- Headquarters
- EmeryVille, United States
- IPO year
- 2023
- Market cap
- $38.6M
- Website
- https://www.estrellabio.com
Loading ESLAW…
Loading profile data…Frequently asked questions about ESLAW
What does Estrella Immunopharma, Inc. (ESLAW) do?
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical firm based in Emeryville, California, dedicated to advancing T-cell immunotherapies for various hematological malignancies and solid tumors within the United States. Its lead investigational treatments include EB103, currently undergoing preclinical assessment for diffuse large B-ce...
Where does ESLAW trade?
Estrella Immunopharma, Inc. (ESLAW) trades on the NASDAQ Capital Market.
What sector is ESLAW in?
Estrella Immunopharma, Inc. (ESLAW) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Estrella Immunopharma, Inc.?
Cheng Liu is the chief executive officer of Estrella Immunopharma, Inc. (ESLAW).
Where is Estrella Immunopharma, Inc. headquartered?
Estrella Immunopharma, Inc. is headquartered in United States.
Does ESLAW pay a dividend?
Estrella Immunopharma, Inc. (ESLAW) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ESLAW go public?
Estrella Immunopharma, Inc. (ESLAW) completed its initial public offering in 2023.